CSL (OTCMKTS:CSLLY) Reaches New 52-Week Low – Should You Sell?

CSL Limited (OTCMKTS:CSLLY) shares hit a new 52-week low during mid-day trading on Monday . The company traded as low as $75.70 and last traded at $79.07, with a volume of 116648 shares traded. The stock had previously closed at $78.95.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a research report on Thursday, January 16th.

CSL Stock Performance

The company has a current ratio of 2.18, a quick ratio of 0.97 and a debt-to-equity ratio of 0.58. The stock’s fifty day simple moving average is $82.30 and its two-hundred day simple moving average is $89.45.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.